On October 18, 2012, Airstrip Technologies, Inc. filed (but did not serve) a single-count complaint in the U.S. District Court for the Southern District of New York, alleging mVisum is in violation of AirStrip’s U.S. 8,255,238 Patent for a “System and Method for Real Time Viewing of Critical Patient Data on Mobile Devices.” mVisum does not infringe any of the claims of the Airstrip patent and as such intends to vigorously defend itself against this groundless allegation, including the filing of counterclaims as may be appropriate.
mVisum's founder and CEO Praveen Dala stated: “mVisum continues to provide clients with the most innovative, user-friendly and cost-effective solutions to address clinical and operational requirements, enhance patient safety, and optimize patient outcomes. This allegation is baseless, and we fully expect a positive outcome. Frivolous litigation has, unfortunately, become commonplace in the United States healthcare system, however, and it is well understood to directly contribute to rising costs. We are confident that the marketplace will readily apprehend these tactics for what they are.”
The above referenced patents issued to mVisum represent only the most recent issuances of multiple patents for over 40 inventions that Dr. Dala has been responsible for over the past 18 years, in addition to many FDA 510(k) clearances that Dr. Dala has also obtained.
mVisum offers mobility solutions and technologies to clinical care providers for receiving, viewing, and responding to all types of patient studies produced by patient information systems including EKGs, alarms, waveforms, images, and much more. mVisum’